» Articles » PMID: 33466402

Immunogenomic Gene Signature of Cell-Death Associated Genes with Prognostic Implications in Lung Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Jan 20
PMID 33466402
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is one of the leading causes of death worldwide. Cell death pathways such as autophagy, apoptosis, and necrosis can provide useful clinical and immunological insights that can assist in the design of personalized therapeutics. In this study, variations in the expression of genes involved in cell death pathways and resulting infiltration of immune cells were explored in lung adenocarcinoma (The Cancer Genome Atlas: TCGA, lung adenocarcinoma (LUAD), 510 patients). Firstly, genes involved in autophagy ( = 34 genes), apoptosis ( = 66 genes), and necrosis ( = 32 genes) were analyzed to assess the prognostic significance in lung cancer. The significant genes were used to develop the cell death index (CDI) of 21 genes which clustered patients based on high risk (high CDI) and low risk (low CDI). The survival analysis using the Kaplan-Meier curve differentiated patients based on overall survival (40.4 months vs. 76.2 months), progression-free survival (26.2 months vs. 48.6 months), and disease-free survival (62.2 months vs. 158.2 months) (Log-rank test, < 0.01). Cox proportional hazard model significantly associated patients in high CDI group with a higher risk of mortality (Hazard Ratio: H.R 1.75, 95% CI: 1.28-2.45, < 0.001). Differential gene expression analysis using principal component analysis (PCA) identified genes with the highest fold change forming distinct clusters. To analyze the immune parameters in two risk groups, cytokines expression ( = 265 genes) analysis revealed the highest association of and (> 1.5-fold, < 0.01) with the high-risk group. The microenvironment cell-population (MCP)-counter algorithm identified the higher infiltration of CD8+ T cells, macrophages, and lower infiltration of neutrophils with the high-risk group. Interestingly, this group also showed a higher expression of immune checkpoint molecules , , and T cell exhaustion genes , , , , , and ) ( < 0.01). Furthermore, functional enrichment analysis identified significant perturbations in immune pathways in the higher risk group. This study highlights the presence of an immunocompromised microenvironment indicated by the higher infiltration of cytotoxic T cells along with the presence of checkpoint molecules and T cell exhaustion genes. These patients at higher risk might be more suitable to benefit from PD-L1 blockade or other checkpoint blockade immunotherapies.

Citing Articles

Single cell transcriptomic analysis reveals tumor immune infiltration by macrophage cells gene signature in lung adenocarcinoma.

Guo X, Deng Y, Jiang W, Li H, Luo Y, Zhang H Discov Oncol. 2025; 16(1):261.

PMID: 40029500 PMC: 11876514. DOI: 10.1007/s12672-025-01834-7.


Pan-cell death-related signature reveals tumor immune microenvironment and optimizes personalized therapy alternations in lung adenocarcinoma.

Han L, He J, Xie H, Gong Y, Xie C Sci Rep. 2024; 14(1):15682.

PMID: 38977778 PMC: 11231366. DOI: 10.1038/s41598-024-66662-1.


Matrix metalloproteinase 9 expression and glioblastoma survival prediction using machine learning on digital pathological images.

Wu Z, Yang Y, Chen M, Zha Y Sci Rep. 2024; 14(1):15065.

PMID: 38956384 PMC: 11220146. DOI: 10.1038/s41598-024-66105-x.


ANXA5: A Key Regulator of Immune Cell Infiltration in Hepatocellular Carcinoma.

Wang W, Liu D, Yao J, Yuan Z, Yan L, Cao B Med Sci Monit. 2024; 30:e943523.

PMID: 38824386 PMC: 11155417. DOI: 10.12659/MSM.943523.


New link between RNH1 and E2F1: regulates the development of lung adenocarcinoma.

Zhao W, Liu Y, Yang Y, Wang L BMC Cancer. 2024; 24(1):635.

PMID: 38783241 PMC: 11118993. DOI: 10.1186/s12885-024-12392-6.


References
1.
He C, Klionsky D . Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009; 43:67-93. PMC: 2831538. DOI: 10.1146/annurev-genet-102808-114910. View

2.
Josefowicz S, Lu L, Rudensky A . Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30:531-64. PMC: 6066374. DOI: 10.1146/annurev.immunol.25.022106.141623. View

3.
Malhotra J, Jabbour S, Aisner J . Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017; 6(2):196-211. PMC: 5420529. DOI: 10.21037/tlcr.2017.03.01. View

4.
Long L, Zhao C, Ozarina M, Zhao X, Yang J, Chen H . Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects. Clin Drug Investig. 2019; 39(4):341-353. DOI: 10.1007/s40261-018-00746-5. View

5.
Burkholder B, Huang R, Burgess R, Luo S, Jones V, Zhang W . Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta. 2014; 1845(2):182-201. DOI: 10.1016/j.bbcan.2014.01.004. View